|
Patent landscape, scope, and claims: |
Executive summary
US Patent 11,986,446 claims a dosing-regimen method for treating cataplexy in narcolepsy and/or excessive daytime sleepiness with GHB (or a GHB prodrug or salt), when the patient is concurrently given divalproex sodium, where the GHB daily dose is reduced to offset PK and/or PD changes attributable to divalproex. The claim scope is tight on: (i) the combination with divalproex, (ii) the reduced daily dosage concept tied to measured PK/PD shifts, and (iii) specific GHB dosing ranges and/or specific reduction percentages in dependent claims. The estate is likely to be valuable for Paragraph IV/section-262(b)(IV)-style method-of-treatment workarounds that hinge on whether a generic or branded alternative either (a) avoids the divalproex co-administration, (b) uses a non-claimed prodrug/salt, (c) does not “reduce to compensate” for measured PK/PD changes, or (d) operates outside the numerical range/percentage limitations used in dependents.
What does US 11,986,446 protect, in plain claim terms? (independent claim scope)
US 11,986,446 claim 1 (and parallel claim 17) protects:
-
Indication and patient condition
- “A patient suffering from cataplexy in narcolepsy or excessive daytime sleepiness.”
-
Active agent
- Administration of gamma-hydroxybutyrate (GHB), described as “a prodrug,” or “a salt thereof.”
- (Practically, the claim is written to cover GHB itself, plus “a prodrug” of GHB, plus salts.)
-
Critical concomitant drug
- The patient is “concomitantly administered divalproex sodium.”
-
Central dosing limitation
- The daily dosage amount of GHB/prodrug/salt is reduced to “compensate for pharmacokinetic (PK) and/or pharmacodynamic (PD) changes caused by concomitant divalproex.”
-
Causal nexus
- The reduction must be tied to changes “caused by” divalproex.
-
Dependent claim scaffolding
- Dependents narrow further using:
- numerical GHB daily doses “in the absence” of divalproex (4.5 to 9.0 g; and specific values 4.5, 6, 7.5, 9),
- prodrug identity (GBL),
- PK/PD measurement methods (CDR tasks; Karolinska Sleepiness Scale K55; plasma concentration, Cmax, Cn, C24, Tmax, AUC),
- adjustment and monitoring,
- reduction magnitude (about 15%–30% or about 20%).
Claim construction risk points (where design-around arguments usually concentrate)
-
“Concomitantly administered divalproex sodium”
- If a competitor’s regimen avoids divalproex co-administration (timing separation, alternative valproate forms, or use of other antiepileptics), it can fall outside the independent claim. This is the single biggest gatekeeper element.
-
“Reduced daily dosage amount … to compensate for PK/PD changes”
- The claim is not merely “dose reduction.” It requires that reduction is for compensating PK/PD changes “caused by” divalproex. That language creates a potential litigation focal point: whether the reduction is protocol-driven to offset interaction-driven exposure/effect differences, not a general titration.
-
Measurement-linked dependents
- Independent claim 1 does not require any specific PK/PD measurement tool. Dependents do. A competitor who adopts a compensatory reduction but does not measure using the claimed methods could potentially avoid dependent claims, while still risking infringement of the independent claim if all independent elements are met.
-
“In the absence of concomitant administration of divalproex sodium”
- This clause matters for dosing-range claim interpretation. Competitors can attempt to argue that any baseline comparison is not the claimed baseline, or uses a different comparator regimen.
-
Numerical dosing ranges and percentage reductions
- Dependents 2, 9–12, 13–14, 18–20, 25–28, 29–30 impose specific numerical limitations. Design-arounds can target operating outside those numerical ranges while still attempting to meet independent claim conceptually (the doctrinal question becomes whether the independent claim is broader than the dependents).
What are the key limitations in the claims of US 11,986,446 and how do they narrow infringement risk?
Featured snippet answer: The claims hinge on a method of treating narcolepsy cataplexy/excessive daytime sleepiness using GHB (or its prodrug/salt) together with divalproex sodium, where the GHB daily dose is reduced to compensate for divalproex-driven PK/PD changes, with dependents adding numerical doses (4.5–9 g) and/or reduction percentages (~15–30% or ~20%), plus optional PK/PD measurement methods and prodrug identity (GBL).
Claim-by-claim narrowers (numerical and measurement dependencies)
Independent
- Claim 1: full concept, no required specific dose number or measurement instrument.
- Claim 17: parallel structure with the same core elements.
Dependent claim narrowing (1–3, 17–19)
- Claim 2 / 18: baseline “absence of divalproex” daily GHB amount between 4.5 and 9.0 g.
- Claim 3 / 19: requires “a reduced daily dosage amount” of a GHB prodrug (as opposed to GHB itself), not necessarily GBL yet.
- Claim 4 / 20: prodrug must be GBL.
Measurement dependents (5–7, 21–23)
- Claim 5 / 21: PD changes measured by:
- Cognitive Drug Research (CDR) system tasks, or
- Karolinska Sleepiness Scale (K55).
- Claim 6 / 22: PK changes measured by one or more of:
- plasma concentration,
- Cmax, Cn, C24, Tmax, AUC.
- Claim 7 / 23: PK changes measured by Cmax or AUC.
Dose adjustment and reduction dependents (8, 13–15, 24, 29–31)
- Claim 8 / 24: includes monitoring and adjusting dose in response to patient response.
- Claim 13 / 29: daily dosage reduction about 15% to 30% compared to baseline “without divalproex.”
- Claim 14 / 30: daily dosage reduction about 20%.
- Claim 15 / 31: patient is currently taking divalproex sodium (often redundant with “concomitantly administered,” but it helps lock down the practice setting).
Specific baseline daily dose dependents (9–12, 25–28)
- Claim 9 / 25: baseline absence-of-divalproex daily amount 4.5 g
- Claim 10 / 26: 6 g
- Claim 11 / 27: 7.5 g
- Claim 12 / 28: 9 g
Practical “risk map” for competitors
- A regimen that meets divalproex + GHB/GBL dose reduction for interaction compensation is exposed to independent claim risk.
- Operating outside the dependent numerical ranges and dependent measurement method likely reduces exposure to dependents, but not necessarily to the independent concept.
Which drug products could infringe US 11,986,446: GHB salts, GBL prodrugs, and divalproex co-therapy?
Core answer: Any product or regimen that results in a patient receiving GHB (or a GHB prodrug or salt) with divalproex sodium, plus a clinician-driven protocol that reduces the GHB daily dose to offset PK/PD changes attributable to divalproex, can fall within the claims.
“Prodrug” coverage (GBL is explicitly named)
- Dependent claims specifically identify the GHB prodrug as gamma butyrolactone (GBL).
- The independent claims also include “a prodrug,” so a competitor using a different GHB prodrug (if it qualifies as a “prodrug” in claim interpretation) can still risk independent claim infringement, but dependent claim coverage may be avoidable.
Salt coverage
- The independent claim includes “or a salt thereof.”
- If a competitor uses a different salt form of GHB, it can still be within independent claim scope if the salt is encompassed by claim construction.
Divalproex identity is rigid
- The concomitant drug is divalproex sodium. Variants (other valproate salts) may or may not be captured depending on whether “divalproex sodium” is interpreted strictly. The dependents and core language strongly emphasize the specific drug identity.
What patents surround US 11,986,446: how broad is the likely estate and what adjacent claim types typically exist?
Answer: With only claim text provided, the full surrounding US and family landscape cannot be reconstructed accurately. However, the claim structure indicates this is likely part of a combination-dosing interaction portfolio rather than a standalone “GHB for narcolepsy” foundational patent.
Likely adjacent claim categories (based on this patent’s theme)
- GHB or prodrug formulations for narcolepsy (if this is in a regulatory history cluster).
- Method-of-use patents for cataplexy/excessive daytime sleepiness using GHB.
- Drug-drug interaction dosing patents with divalproex and/or other CNS co-therapies.
- PK/PD measurement methodologies for tailoring GHB dosing.
Litigation posture relevance
This claim set is drafted to enable enforcement against specific clinical protocols rather than against a bulk product alone. That typically affects:
- how settlements are negotiated,
- whether licensing is needed for method execution,
- and whether label-driven practice can be argued as non-infringing.
How strong is the patent estate for this dosing interaction: scope, definiteness, and enforceability factors?
Scope strength
- The claims are narrow and clinically specific:
- specific indication area (cataplexy in narcolepsy/excessive daytime sleepiness),
- a specific concomitant (divalproex),
- a specific pharmacological compensatory concept (dose reduction to offset divalproex-driven PK/PD changes).
Enforceability leverage
- Strong enforcement hook exists when:
- divalproex co-therapy is standard in a patient subpopulation, and
- clinicians follow titration/dose reduction protocols that explicitly or implicitly aim to counter interaction effects.
Vulnerability points
- The independent claim uses broad language around PK/PD changes and compensation without requiring a named assay or exact percentage. That can cut both ways:
- It can broaden infringement coverage for routine clinical practice.
- It can also be challenged as difficult to prove “compensated for PK/PD changes caused by divalproex,” depending on evidence available in a specific case.
Dependent claim value
- Dependent claims provide clean numeric anchors:
- baseline daily dose: 4.5–9.0 g and exact values,
- reduction magnitudes: ~15–30% or ~20%,
- measurement instruments: CDR tasks and K55, PK parameters including Cmax and AUC.
- Those anchors can facilitate infringement case theories with trial protocol documentation or prescriber adjustment records.
When does US 11,986,446 lose exclusivity? What are the expiration timelines?
No filing date, priority date, prosecution history, adjustment, terminal disclaimer, or PTA data is provided in the prompt. Without those, accurate expiration or exclusivity timing cannot be produced.
What generic entry risks exist for cataplexy/narcolepsy GHB regimens using divalproex?
Answer: Entry risk primarily concerns method-of-treatment infringement, not product-level infringement. A generic manufacturer typically reduces risk by:
- avoiding instructions or marketing that encourage the claimed regimen, and/or
- ensuring that co-administration and compensatory dose reduction are not part of the claimed method in a provable way.
However, the independent claim is directed to a method; if actual practice includes divalproex co-therapy and dose reduction “to compensate” for interaction-driven PK/PD effects, risk remains regardless of labeling in some jurisdictions, depending on how courts treat induced or contributory infringement and evidence of the method’s performance.
Orange Book status and FDA pathway: what is the regulatory posture of a method claim like this?
Answer: Orange Book listings apply to drug products and approved formulations, not directly to a method-of-treatment patent that is enforceable against clinical practice. Without the linked drug product identity and Orange Book entry, exact status cannot be stated.
What patent litigation affects US 11,986,446 and how do settlements change launch timing?
No litigation docket, listed defendants, or settlement terms are provided. Without those, a litigation impact assessment cannot be constructed.
Claim coverage comparisons: how do the independent claims 1 and 17 align and what differences matter?
Claim 1 and claim 17 are parallel:
- Both cover:
- treatment of cataplexy in narcolepsy or excessive daytime sleepiness,
- administration of GHB/prodrug/salt with concomitant divalproex sodium,
- reduction of daily dose to compensate for divalproex-caused PK/PD changes.
- Differences are cosmetic (claim language variants), with the same dependency structure in both claim sets.
Practical impact
- Parallel independent claims reduce the chance of total invalidity via a single drafting flaw, and they support multiple enforcement pathways.
Detailed claim chart: infringement elements mapped to the provided claim text
| Element |
Where in claims |
What must be shown in practice |
| Patient has cataplexy in narcolepsy and/or excessive daytime sleepiness |
Claim 1; Claim 17 |
Indication/patient condition |
| Administer GHB OR GHB prodrug OR salt |
Claim 1; Claim 17 |
Drug administration includes GHB/prodrug/salt |
| Concomitant divalproex sodium |
Claim 1; Claim 17; dep. 15/31 |
Divalproex is co-administered |
| Reduce daily dosage amount |
Claim 1; Claim 17 |
Lower GHB daily dose in the presence of divalproex |
| Reduction compensates for PK and/or PD changes caused by divalproex |
Claim 1; Claim 17 |
Dose reduction is designed/performed to offset interaction-driven changes |
| Optional measurement methods |
Claim 5–7; 21–23 |
CDR tasks/K55 or PK parameters measured |
| Optional dose numbers |
Claim 2, 9–12; 18, 25–28 |
Baseline absence-of-divalproex daily dose 4.5–9 g (or exact values) |
| Optional reduction percentages |
Claim 13–14; 29–30 |
Reduction about 15–30% or about 20% |
| Optional prodrug identity |
Claim 4; 20 |
Prodrug is GBL |
| Optional monitoring and adjusting |
Claim 8; 24 |
Monitor response and adjust |
Key Takeaways
- US 11,986,446 is a dosing-interaction method patent focused on GHB (or prodrug/salt) dose reduction when divalproex sodium is concomitantly administered in patients with narcolepsy cataplexy and/or excessive daytime sleepiness.
- The independent claims are broad on what counts as PK/PD changes and what measurement methods are required (none in the independent). Dependents add specific numerical baseline doses, reduction percentages, and PK/PD measurement tools.
- Enforceability and design-around strategies will turn on evidence of: divalproex co-administration, that the dose was reduced to compensate for interaction-driven PK/PD changes, and whether the regimen falls within dependent numerical limits.
- Without priority/prosecution/FDA linkage data, expiration timelines and Orange Book status cannot be determined from the prompt.
FAQs
-
Can a regimen that reduces GHB dose for general tolerability avoid US 11,986,446?
Risk remains if the reduction is performed “to compensate for” divalproex-caused PK/PD changes; proving intent/purpose versus general titration becomes central.
-
Does using a GHB prodrug other than GBL avoid dependent claim 4/20?
It may avoid the specific dependent limitation identifying GBL, but independent claim exposure persists if the prodrug qualifies and the other elements are met.
-
If PK/PD are not measured using CDR tasks or K55, is the method still covered?
Those measurement tools are in dependent claims. Independent claim coverage can still attach if all independent limitations are satisfied.
-
What is the most effective design-around target: divalproex or the dose reduction element?
The divalproex concomitant element is the primary gatekeeper; avoiding concomitant divalproex co-administration is the cleanest approach, while avoiding the compensatory reduction linkage can be difficult to prove.
-
How do the “absence of concomitant administration” baseline doses affect infringement analysis?
Dependents require a defined baseline daily dose range (4.5–9.0 g) or specific values (4.5/6/7.5/9 g) absent divalproex, impacting whether those dependents are satisfied.
References (APA)
- US Patent 11,986,446 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
